DK2101877T3 - Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo - Google Patents

Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo

Info

Publication number
DK2101877T3
DK2101877T3 DK07857153T DK07857153T DK2101877T3 DK 2101877 T3 DK2101877 T3 DK 2101877T3 DK 07857153 T DK07857153 T DK 07857153T DK 07857153 T DK07857153 T DK 07857153T DK 2101877 T3 DK2101877 T3 DK 2101877T3
Authority
DK
Denmark
Prior art keywords
neutralization
vivo
effect
glioblastoma cells
block invasion
Prior art date
Application number
DK07857153T
Other languages
English (en)
Inventor
Ignacio Sancho-Martinez
Benedikt Wiestler
Ana Martin-Villalba
Susanne Kleber
Peter G Krammer
Christel Herold-Mende
Original Assignee
Deutsches Krebsforsch
Universitaetsklinikum Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Universitaetsklinikum Heidelberg filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK2101877T3 publication Critical patent/DK2101877T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK07857153T 2006-12-28 2007-12-28 Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo DK2101877T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87736706P 2006-12-28 2006-12-28
PCT/EP2007/011461 WO2008080623A2 (en) 2006-12-28 2007-12-28 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo

Publications (1)

Publication Number Publication Date
DK2101877T3 true DK2101877T3 (da) 2013-09-23

Family

ID=39400900

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07857153T DK2101877T3 (da) 2006-12-28 2007-12-28 Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
DK11190918T DK2428252T3 (da) 2006-12-28 2007-12-28 Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11190918T DK2428252T3 (da) 2006-12-28 2007-12-28 Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo

Country Status (12)

Country Link
US (2) US9309320B2 (da)
EP (2) EP2428252B1 (da)
JP (2) JP5558828B2 (da)
AU (1) AU2007341631B9 (da)
CA (1) CA2673868C (da)
CY (1) CY1116006T1 (da)
DK (2) DK2101877T3 (da)
ES (2) ES2523992T3 (da)
PL (2) PL2101877T3 (da)
PT (2) PT2101877E (da)
SI (1) SI2428252T1 (da)
WO (1) WO2008080623A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657801T3 (es) 2007-07-10 2018-03-06 Apogenix Ag Proteínas de fusión de colectina de la superfamilia de TNF
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
WO2011010156A1 (en) * 2009-07-21 2011-01-27 Queen Mary & Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
CA2877989C (en) * 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
MX363679B (es) * 2013-04-29 2019-03-29 Apogenix Ag Metodo para diagnosticar cancer.
WO2014186878A1 (en) 2013-05-24 2014-11-27 Cashman Neil R Cell senescence markers as diagnostic and therapeutic targets
EP3094744A1 (en) * 2014-01-15 2016-11-23 Apogenix AG Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
AU2019403393B2 (en) 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CN116157513A (zh) 2020-08-18 2023-05-23 昂希莱斯制药公司 经修饰的猪胰腺弹性蛋白酶蛋白

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
MX9306682A (es) 1992-10-30 1994-04-29 Bristol Myers Squibb Co Ligandos del receptor de la matriz extracelular, que modulan la funcion de los leucocitos.
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
AU716731B2 (en) 1995-03-20 2000-03-02 Ko Okumura Monoclonal antibody reacting specifically with Fas ligand and process for producing the same
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
JPH09124509A (ja) 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
WO1997042319A1 (en) 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. NOVEL Fas ANTIGEN DERIVATIVES
WO1998010070A1 (en) 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. HUMANIZED IMMUNOGLOBULIN REACTING SPECIFICALLY WITH Fas LIGAND OR ACTIVE FRAGMENTS THEREOF AND REGION INDUCING APOPTOSIS ORIGINATING IN Fas LIGAND
PT1015587E (pt) 1997-09-18 2008-07-31 Genentech Inc Polipéptido dcr3, um homólogo de tnfr
IL138626A0 (en) 1998-03-30 2001-10-31 Lilly Co Eli Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily
US6348573B1 (en) * 1998-04-27 2002-02-19 The Regents Of The University Of Michigan Compositions and methods for identifying apoptosis signaling pathway inhibitors and activators
EP1087993B1 (en) 1998-06-18 2008-04-02 Imed Ab Fas peptides and antibodies for modulating apoptosis
US20030170244A1 (en) * 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
AU2003226370A1 (en) * 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
DK1606318T3 (da) * 2003-03-26 2009-11-02 Apogenix Gmbh Forbedrede Fc-fusionsproteiner
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors

Also Published As

Publication number Publication date
ES2420582T3 (es) 2013-08-26
AU2007341631B2 (en) 2012-08-30
WO2008080623A2 (en) 2008-07-10
JP2014167024A (ja) 2014-09-11
US20100322922A1 (en) 2010-12-23
EP2428252A1 (en) 2012-03-14
JP2010514722A (ja) 2010-05-06
CY1116006T1 (el) 2017-01-25
US9309320B2 (en) 2016-04-12
PL2101877T3 (pl) 2013-11-29
PT2428252E (pt) 2014-12-11
ES2523992T3 (es) 2014-12-03
WO2008080623A3 (en) 2008-09-12
CA2673868C (en) 2016-03-22
SI2428252T1 (sl) 2015-01-30
EP2101877B1 (en) 2013-06-19
DK2428252T3 (da) 2015-02-16
US9850308B2 (en) 2017-12-26
CA2673868A1 (en) 2008-07-10
JP5893078B2 (ja) 2016-03-23
EP2101877A2 (en) 2009-09-23
JP5558828B2 (ja) 2014-07-23
AU2007341631A1 (en) 2008-07-10
PL2428252T3 (pl) 2015-04-30
US20160115236A1 (en) 2016-04-28
PT2101877E (pt) 2013-07-22
AU2007341631B9 (en) 2012-10-04
EP2428252B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
PT2428252E (pt) Neutralização de atividade de blocos de invasão cd95 de células de glioblastoma in vivo
IL240524A0 (en) Activin-actrii antagonists and uses for increasing red blood cell levels
BR112012014158A2 (pt) "célula eletroquímica"
FR2928157B1 (fr) Module de cellule habitable et cellule habitable correspondante
PT3037529T (pt) Polipéptidos ph20 estendidos solúveis e suas utilizações
EP2005504A4 (en) ELECTROLYTE
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
EP2213018A4 (en) Random access cyclic prefix dimensioning in wireless networks
BRPI0821042A2 (pt) Célula de lítio
BRPI0922084A2 (pt) Composições e métodos compreendendo variantes de serina protease
BRPI0921822A2 (pt) composição compreendendo polímero e enzima
BRPI0912201A2 (pt) células formadoras de colônias de hemangios e células de hemangio não enxertantes
DK2207415T3 (da) Elektrokemisk indretning til biocidbehandling i landbrugsanvendelser
EP2095430A4 (en) SOLAR CELL
EP2095104A4 (en) ILLUSTRATION OF TWO-DIMENSIONAL ARRAYS
DK2257618T3 (da) Fremstilling af glykosylerede polypeptider i mikroalger
EP2340303A4 (en) AMNION FLUID CELLS AND USES THEREOF
DK2493291T3 (da) Peham-dendrimerer til anvendelse i landbrug
DK2027150T3 (da) Allo-begrænsede peptid-specifikke t-celler
BRPI0907886A2 (pt) Célula de lítio
EP2279201A4 (en) PEPTIDES APPLIED TO APOPTOTIC CELLS AND THEIR USE
DK2379995T3 (da) Vejecelle
EP2095405A4 (en) SOLAR CELLS
BRPI0922246A2 (pt) copolímero contendo blocos de construção ácida e vários tipos de blocos de construção de poliéter.
BRPI0918579A2 (pt) composição de gel tensoativa